Breaking News Instant updates and real-time market news.

INCY

Incyte

$64.02

-19.05 (-22.93%)

07:57
04/09/18
04/09
07:57
04/09/18
07:57

Incyte price target lowered to $76 from $142 at Morgan Stanley

Morgan Stanley analyst Thomas Smith lowered his price target on Incyte to $76 after removing epacadostat from his model following the announcement that the ECHO-301 trial failed to show benefit over PD-1 monotherapy in melanoma. However, Smith believes Incyte shares already reflected a significant amount of investor skepticism heading into the ECHO-301 data and he views the company as having one of the deepest pipelines in SMID-cap biotech, supported by the Jakafi base business in myelofibrosis, Iclusig royalties in Europe and royalties from baricitinib. Smith keeps an Overweight rating on Incyte shares.

  • 23

    Apr

  • 12

    Jun

INCY Incyte
$64.02

-19.05 (-22.93%)

04/09/18
OPCO
04/09/18
NO CHANGE
Target $65
OPCO
Perform
Incyte price target lowered to $65 from $110 at Oppenheimer
Oppenheimer analyst Jay Olson lowered his price target for Incyte (INCY) to $65 from $110 following the update on the termination of ECHO-301 after epacadostat failed to show a PFS or OS benefit when combined with Merck's (MRK) Keytruda versus Keytruda alone. While the company plans to conduct subgroup analyses of ECHO-301 looking at various biomarkers such as PD-L1 expression and tumor mutational burden which may provide additional insights, the analyst sees no reason at this time to continue development of epacadostat as he considers it highly unlikely to demonstrate efficacy in other tumor types and/or combinations. Olson reiterates a Perform rating on Incyte's shares.
04/09/18
NOMU
04/09/18
NO CHANGE
Target $102
NOMU
Buy
Incyte price target lowered to $102 from $139 at Nomura Instinet
Nomura Instinet analyst Christopher Marai on Friday lowered his price target for Incyte to $102 after the Phase ECHO-301 trial of epacadostat and pembrolizumab in advanced metastatic melanoma was stopped. The analyst keeps a Buy rating on the shares. He tells investors to focus on the company's TKI pipeline.
04/09/18
RHCO
04/09/18
DOWNGRADE
Target $5
RHCO
Hold
NewLink Genetics downgraded to Hold at SunTrust on Incyte trial failure
As reported late last week, SunTrust analyst Peter Lawson downgraded NewLink Genetics (NLNK) to Hold from Buy and lowered his price target to $5 from $19. Lawson cites the announcement of negative results from the Phase 3 ECHO-301 of epacadostat + Keytruda in melanoma by Incyte (INCY), saying the data also implies a "significant negative read through for NewLink's IDO agent, indoximod". Lawson adds that the results have led him to remove melanoma from his NewLink model and also reduce the probability of success in pancreatic cancer, lowering the probability of adjusted peak sales from $415M to just $11M.
04/09/18
HCWC
04/09/18
NO CHANGE
Target $125
HCWC
Buy
Nektar data 'more robust' than Incyte's, says H.C. Wainwright
The failure of Incyte (INCY) and Merck's (MRK) Phase 3 study negatively impacted trading in Nektar Therapeutics (NKTR) shares on Friday, H.C. Wainwright analyst Debjit Chattopadhyay tells investors in a research note titled "Collateral Damage Not Surprising; Expecting ASCO-18 to Validate the Master T Cell Regulator Hypothesis." At this year's American Society of Clinical Oncology meeting, the analyst expects Nektar and partner Bristol-Myers Squibb (BMY) to unveil data from at least 40 advanced melanoma patients "supported by in-depth biomarker characterization to comprehensively ascertain the rationale of combining NKTR-214 with Opdivo." The rationale for combining NKTR-214 with Opdivo is "more robust" than epacadostat plus Keytruda, the analyst contends. Further, he believes data generated by the NKTR-214 plus Opdivo combination is "unambiguous." Chattopadhyay reiterates a Buy rating on Nektar shares with a $125 price target.

TODAY'S FREE FLY STORIES

LOW

Lowe's

$86.15

-5.19 (-5.68%)

08:36
11/21/18
11/21
08:36
11/21/18
08:36
Recommendations
Lowe's analyst commentary  »

Lowe's price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMB

Limbach Holding

$4.85

-1.04 (-17.66%)

, FIX

Comfort Systems USA

$52.64

-1.06 (-1.97%)

08:35
11/21/18
11/21
08:35
11/21/18
08:35
Recommendations
Limbach Holding, Comfort Systems USA, Emcore analyst commentary  »

Limbach Holding price…

LMB

Limbach Holding

$4.85

-1.04 (-17.66%)

FIX

Comfort Systems USA

$52.64

-1.06 (-1.97%)

EMKR

Emcore

$4.42

-0.02 (-0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:34
11/21/18
11/21
08:34
11/21/18
08:34
General news
Jobless Claims data reported »

Week of 11/17 Jobless…

DXCM

DexCom

$119.89

-1.34 (-1.11%)

, GOOG

Alphabet

$1,026.00

7 (0.69%)

08:33
11/21/18
11/21
08:33
11/21/18
08:33
Recommendations
DexCom, Alphabet, Alphabet Class A analyst commentary  »

Verily collaboration more…

DXCM

DexCom

$119.89

-1.34 (-1.11%)

GOOG

Alphabet

$1,026.00

7 (0.69%)

GOOGL

Alphabet Class A

$1,031.22

4.99 (0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Nov

  • 04

    Dec

  • 03

    Mar

LUXTY

Luxottica

$0.00

(0.00%)

08:31
11/21/18
11/21
08:31
11/21/18
08:31
Downgrade
Luxottica rating change  »

Luxottica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGCO

Agco

$57.86

0.5 (0.87%)

, DE

Deere

$138.49

-4.04 (-2.83%)

08:29
11/21/18
11/21
08:29
11/21/18
08:29
Hot Stocks
Agco drops 2% after Deere issues FY19 guidance »

Shares of farm equipment…

AGCO

Agco

$57.86

0.5 (0.87%)

DE

Deere

$138.49

-4.04 (-2.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

USCR

U.S. Concrete

$34.14

-1.6 (-4.48%)

08:25
11/21/18
11/21
08:25
11/21/18
08:25
Recommendations
U.S. Concrete analyst commentary  »

U.S. Concrete price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

HUM

Humana

$307.50

-2.87 (-0.92%)

, WBA

Walgreens Boots Alliance

$79.82

-2.11 (-2.58%)

08:25
11/21/18
11/21
08:25
11/21/18
08:25
Recommendations
Humana, Walgreens Boots Alliance, Amazon.com, CVS Health, Aetna, UnitedHealth analyst commentary  »

Humana-Walgreens…

HUM

Humana

$307.50

-2.87 (-0.92%)

WBA

Walgreens Boots Alliance

$79.82

-2.11 (-2.58%)

AMZN

Amazon.com

$1,495.60

-16.07 (-1.06%)

CVS

CVS Health

$75.52

-3.02 (-3.85%)

AET

Aetna

$204.15

-3.535 (-1.70%)

UNH

UnitedHealth

$261.52

-4.52 (-1.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 27

    Nov

  • 27

    Nov

  • 28

    Nov

  • 28

    Nov

  • 02

    Dec

  • 04

    Dec

$DJT

DJ Transportation Average

$0.00

(0.00%)

08:21
11/21/18
11/21
08:21
11/21/18
08:21
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$DJU

DJ Utility Average

$0.00

(0.00%)

08:20
11/21/18
11/21
08:20
11/21/18
08:20
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

08:20
11/21/18
11/21
08:20
11/21/18
08:20
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JEC

Jacobs Engineering

$65.06

-7.9 (-10.83%)

08:20
11/21/18
11/21
08:20
11/21/18
08:20
Recommendations
Jacobs Engineering analyst commentary  »

Jacobs Engineering shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 19

    Feb

IYT

iShares Transportation Average

$184.16

-5.75 (-3.03%)

08:20
11/21/18
11/21
08:20
11/21/18
08:20
Technical Analysis
iShares Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:20
11/21/18
11/21
08:20
11/21/18
08:20
General news
U.S. Durable Goods Preview »

U.S. Durable Goods…

08:20
11/21/18
11/21
08:20
11/21/18
08:20
General news
U.S. initial jobless claims preview: »

U.S. initial jobless…

XLK

Technology Select Sector SPDR

$64.22

-1.42 (-2.16%)

08:19
11/21/18
11/21
08:19
11/21/18
08:19
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$64.98

-2.17 (-3.23%)

08:19
11/21/18
11/21
08:19
11/21/18
08:19
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLY

Consumer Discretionary Sector SPDR

$101.42

-2.35 (-2.26%)

08:19
11/21/18
11/21
08:19
11/21/18
08:19
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLB

S&P Select Materials SPDR

$53.45

-1 (-1.84%)

08:19
11/21/18
11/21
08:19
11/21/18
08:19
Technical Analysis
S&P Select Materials SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLU

Utilities SPDR

$54.85

-0.28 (-0.51%)

08:18
11/21/18
11/21
08:18
11/21/18
08:18
Technical Analysis
Utilities SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLP

Consumer Staples Sector SPDR

$55.02

-0.93 (-1.66%)

08:18
11/21/18
11/21
08:18
11/21/18
08:18
Technical Analysis
Consumer Staples Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLV

Health Care Select Sector SPDR

$89.97

-0.9 (-0.99%)

08:18
11/21/18
11/21
08:18
11/21/18
08:18
Technical Analysis
Health Care Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMB

Limbach Holding

$4.85

-1.04 (-17.66%)

08:18
11/21/18
11/21
08:18
11/21/18
08:18
Downgrade
Limbach Holding rating change  »

Limbach Holding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGMS

Scientific Games

$15.96

-1.22 (-7.10%)

08:18
11/21/18
11/21
08:18
11/21/18
08:18
Hot Stocks
Scientific Games launches eInstant and digital games with Norwegian lottery »

Scientific Games has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IWM

iShares Trust Russell 2000 Index Fund

$146.05

-2.88 (-1.93%)

08:18
11/21/18
11/21
08:18
11/21/18
08:18
Technical Analysis
iShares Trust Russell 2000 Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.